During COVID-19, researchers found that low-dose buprenorphine initiation for fentanyl users was largely unsuccessful, with ...

Access to the new Alzheimer's drugs is limited by strict eligibility criteria, long wait times, and a lack of infusion centers.

Eisai is seeking approval for an injectable version of Leqembi while Eli Lilly is developing a new injectable drug. These ...